Skip Navigation LinksHome > June 2009 - Volume 4 - Issue 6 > EBUS-TBNA for the Mediastinal Staging of Non-small Cell Lung...
Journal of Thoracic Oncology:
doi: 10.1097/JTO.0b013e3181a52e4d
Letters to the Editor

EBUS-TBNA for the Mediastinal Staging of Non-small Cell Lung Cancer

Navani, Neal MA, MRCP; Spiro, Stephen G. MD, FRCP; Janes, Sam M. MRCP, MSc, PhD

Free Access
Article Outline
Collapse Box

Author Information

Centre for Respiratory Research, University College London, United Kingdom, n.navani@ucl.ac.uk

Disclosure: The authors declare no conflicts of interest.

Back to Top | Article Outline

To the Editor:

The mediastinal staging of non-small cell lung cancer is an important process that distinguishes operable from inoperable candidates. In their retrospective study, Rintoul et al.1 report the utility of endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) for the diagnosis of positron emission tomography (PET) positive mediastinal and hilar lymph nodes. They demonstrate a sensitivity of EBUS-TBNA of 91% when reference pathology was available.

The high false-positive rate of PET for the detection of mediastinal metastases demands that PET-positive mediastinal nodes should be invasively sampled and proven to contain metastatic disease before radical treatment is precluded. However, in addition to a high false-positive rate, it is increasingly recognized that PET is associated with a significant false-negative rate. The pooled sensitivity of PET for detecting mediastinal metastases from a meta-analysis was 0.74 (95% CI 0.69-0.79) and therefore PET scanning fails to detect over a quarter of mediastinal metastases in non-small cell lung cancer.2 This is reflected by current guidelines which suggest that all mediastinal lymph nodes ≥1 cm should be sampled preoperatively, regardless of fluorodeoxyglucose-avidity.3 Emerging data also suggests that malignancy can be detected in PET negative mediastinal nodes that are less than 1 cm in short axis.4 Therefore, a strategy where PET positive mediastinal lymph nodes alone are sampled should not be advocated.

The value of PET lies in its ability to detect radiographically occult extrathoracic metastases5 and should be applied preoperatively in all cases. However, EBUS-TBNA has a higher sensitivity for the detection of mediastinal metastases than PET. Therefore restricting the application of EBUS-TBNA to only PET positive mediastinal nodes would miss mediastinal metastases preoperatively and result in futile thoracotomies.

Neal Navani, MA, MRCP

Stephen G. Spiro, MD, FRCP

Sam M. Janes, MRCP, MSc, PhD

Centre for Respiratory Research

University College London

United Kingdom

n.navani@ucl.ac.uk

Back to Top | Article Outline

REFERENCES

1. Rintoul RC, Tournoy KG, El Daly H, et al. EBUS-TBNA for the clarification of PET positive intra-thoracic lymph nodes-an international multi-centre experience. J Thorac Oncol 2009;4:44–48.

2. Silvestri GA, Gould MK, Margolis ML, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007;132:178S–201S.

3. Detterbeck FC, Jantz MA, Wallace M, Vansteenkiste J, Silvestri GA. Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:202S–220S.

4. Herth FJ, Eberhardt R, Krasnik M, Ernst A. Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer. Chest 2008;133:887–891.

5. Macmanus MP, Hicks RJ, Matthews JP, et al. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:287–293.

© 2009International Association for the Study of Lung Cancer

Login

Article Tools

Share

Other Ways to Connect

Twitter
twitter.com/JTOonline

 



Visit JTO.org on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.

 For additional oncology content, visit LWW Oncology Journals on Facebook.